ScreenerHero

ORKA Oruka Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · orukatx.com
78.16USD-1.69%Mkt Cap: 5.26B $P/E: —

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap5.26B USD
Enterprise Value4.44B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-105.43M USD
Revenue/Share—
Last Price78.16 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-28.01
PEG—
EV/EBITDA-28.66
EV/Revenue—
P/S—
P/B4.41
EPS (TTM)-2.04
EPS (Forward)-2.86
52W Range
14.8963% of range115.51
52W High115.51 USD
52W Low14.89 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-22.48%
ROA-21.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.21M USD
CapEx (TTM)209.00K USD
FCF Margin—
FCF Yield-1.24%
Net Debt-871.02M USD
Net Debt/EBITDA5.62
Balance Sheet
Debt/Equity0.00
Current Ratio38.51
Quick Ratio38.03
Book Value/Sh18.20 USD
Cash/Share13.19 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateAug 28, 2024
Splits
Last Split1:12
Split DateSep 3, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)155.00 USD
Upside (mean)+98.3%
Target Range117.00 USD – 200.00 USD
117.00+98.3% to mean200.00
# Analysts12
Ownership
Shares Out.66.21M
Float56.89M
Insiders1.26%
Institutions116.60%
Short Interest
Short Ratio9.9d
Short % Float16.76%
Short % Out.11.51%
Shares Short7.62M
Short (prev mo.)8.30M
Technical
SMA 5095.41 (-18.1%)
SMA 20064.46 (+21.3%)
Beta-0.11
S&P 52W Chg16.45%
Avg Vol (30d)904.02K
Avg Vol (10d)1.09M
Technical Indicators
RSI (14)31.1
MACD-3.8251
MACD Signal-3.0245
MACD Hist.-0.8005
BB Upper99.03 USD
BB Middle88.14 USD
BB Lower77.26 USD
BB Width24.69%
ATR (14)4.645 USD
Vol Ratio (20d)0.84x